Biogen (BIIB) Stock: Buy, Sell, or Hold?
BIIB - Biogen Inc. Common Stock
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 4, 2026 at $220.83 · last confirmed Sep 9, 2026
Get Alerted When BIIB Hits Your Target Price
Join 10,000+ traders who never miss a move
Interactive Price Chart (1 Month)
Loading historical data...
âšī¸ NEUTRAL: BIIB is fairly priced but lacks strong directional signals. At 3.4% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.9x Exit PE.
In-depth Analysis How we analyze
Technical Outlook: Technically, BIIB is in a strong uptrend. Immediate support is located at $208.93, while resistance sits at $225.80.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Protect Your Profits
Holding BIIB? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($236.87)
- BULLISH: Expecting earnings turnaround to 3.4% growth with 3.4% revenue growth
- WARNING: Composite score 47/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
Support & Resistance Levels
Fundamental Context
Data refreshes hourly during market hours. Next update: 5:45 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Is BIIB showing a specific setup today?
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1319 | 47 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 44 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$277 | 53 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$388 | 43 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$153 | 42 HOLD |
Advanced BIIB Option Strategies
Professional options setups generated by AI based on today's BIIB price and gamma walls.
